Total Payments
$638,492
2024 Payments
$27,970
Companies
28
Transactions
883
Medicare Patients
2,433
Medicare Billing
$283,282
Payment Breakdown by Category
Consulting$227,252 (35.6%)
Other$213,485 (33.4%)
Travel$104,065 (16.3%)
Research$71,213 (11.2%)
Food & Beverage$22,368 (3.5%)
Education$82.92 (0.0%)
Gifts$24.61 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $227,252 | 94 | 35.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $107,619 | 44 | 16.9% |
| Travel and Lodging | $104,065 | 218 | 16.3% |
| Honoraria | $96,367 | 39 | 15.1% |
| Unspecified | $71,213 | 27 | 11.2% |
| Food and Beverage | $22,368 | 454 | 3.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $9,500 | 1 | 1.5% |
| Education | $82.92 | 5 | 0.0% |
| Gift | $24.61 | 1 | 0.0% |
Payments by Type
General
$567,278
856 transactions
Research
$71,213
27 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GRT US Holding, Inc. | $160,290 | 231 | $0 (2023) |
| Allergan, Inc. | $156,286 | 233 | $0 (2022) |
| MERZ NORTH AMERICA, INC. | $108,168 | 107 | $0 (2020) |
| Alexion Pharmaceuticals, Inc. | $50,254 | 56 | $0 (2024) |
| CSL Behring | $43,919 | 17 | $0 (2019) |
| Merz Pharmaceuticals, LLC | $29,079 | 44 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $17,299 | 19 | $0 (2023) |
| Merz Pharmaceuticals GmbH | $12,897 | 9 | $0 (2017) |
| Shionogi Inc | $9,589 | 9 | $0 (2024) |
| ARGENX US, INC. | $9,254 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27,970 | 44 | Merz Pharmaceuticals, LLC ($12,751) |
| 2023 | $19,466 | 69 | Alexion Pharmaceuticals, Inc. ($13,016) |
| 2022 | $101,194 | 209 | GRT US Holding, Inc. ($85,209) |
| 2021 | $85,117 | 147 | GRT US Holding, Inc. ($55,801) |
| 2020 | $87,857 | 74 | MERZ NORTH AMERICA, INC. ($31,105) |
| 2019 | $73,174 | 119 | Merz North America, Inc. ($23,881) |
| 2018 | $84,460 | 91 | Allergan Inc. ($43,098) |
| 2017 | $159,253 | 130 | Allergan Inc. ($75,634) |
All Payment Transactions
883 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/28/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Consulting Fee | Cash or cash equivalent | $7,500.00 | General |
| Category: Neurology | ||||||
| 12/28/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: Neurology | ||||||
| 12/18/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 12/16/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Neurology | ||||||
| 11/15/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Neurology | ||||||
| 11/15/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Neurology | ||||||
| 11/15/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $46.14 | General |
| Category: Neurology | ||||||
| 11/15/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $43.42 | General |
| Category: Neurology | ||||||
| 11/14/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $628.06 | General |
| Category: Neurology | ||||||
| 11/14/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $303.03 | General |
| Category: Neurology | ||||||
| 11/14/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $183.33 | General |
| Category: Neurology | ||||||
| 11/14/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $106.08 | General |
| Category: Neurology | ||||||
| 11/08/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 10/09/2024 | ARGENX US, INC. | — | Food and Beverage | In-kind items and services | $124.99 | General |
| 10/09/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $26.42 | General |
| Category: PAIN MANAGEMENT | ||||||
| 09/16/2024 | Grifols USA, LLC | Gamunex-C (Biological) | Food and Beverage | In-kind items and services | $134.81 | General |
| Category: Immunology and Neurology | ||||||
| 06/19/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Consulting Fee | Cash or cash equivalent | $1,860.00 | General |
| Category: Musculoskeletal | ||||||
| 06/06/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $187.75 | General |
| Category: PAIN MANAGEMENT | ||||||
| 04/26/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $45.93 | General |
| Category: PAIN MANAGEMENT | ||||||
| 04/23/2024 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 04/17/2024 | Xeris Pharmaceuticals, Inc. | KEVEYIS (Drug) | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: Carbonic anhydrase inhibitor | ||||||
| 04/09/2024 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $159.80 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 04/04/2024 | Xeris Pharmaceuticals, Inc. | KEVEYIS (Drug) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Carbonic anhydrase inhibitor | ||||||
| 03/28/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: PAIN MANAGEMENT | ||||||
| 03/26/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $33.43 | General |
| Category: BOTOX THERAPEUTIC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Double-blind, Placebo Controlled study of Intravenous Immunoglobulin for HIV Associated Myelopathy | CSL Behring | $37,667 | 1 |
| PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF NT 201 IN THE TREATMENT OF LOWER LIMB SPASTICITY CAUSED BY STROKE OR TRAUMATIC BRAIN INJURY IN ADULT SUBJECTS, FOLLOWED BY AN OPEN LABEL EXTENSION WITH OR WITHOUT COMBINED UPPER LIMB TREATMENT | MERZ NORTH AMERICA, INC. | $24,706 | 17 |
| PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF NT 201 IN THE TREATMENT OF LOWER LIMB SPASTICITY CAUSED BY STROKE OR TRAUMATIC BRAIN INJURY IN ADULT SUBJECTS, FOLLOWED BY AN OPEN LABEL EXTENSION WITH OR WITHOUT COMBINED UPPER LIMB TREATMENT | Merz North America, Inc. | $6,186 | 8 |
| Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment | Merz Pharmaceuticals, LLC | $2,654 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 648 | 859 | $335,651 | $79,863 |
| 2022 | 14 | 552 | 742 | $280,302 | $68,410 |
| 2021 | 13 | 678 | 858 | $342,944 | $80,843 |
| 2020 | 15 | 555 | 730 | $297,065 | $54,166 |
Total Patients
2,433
Total Services
3,189
Medicare Billing
$283,282
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 124 | 173 | $76,120 | $21,536 | 28.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 66 | 66 | $44,220 | $10,462 | 23.7% |
| 95913 | Nerve conduction, 13 or more studies | Facility | 2023 | 58 | 58 | $42,920 | $9,468 | 22.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 67 | 97 | $30,070 | $8,099 | 26.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 53 | 77 | $33,110 | $6,392 | 19.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 36 | 51 | $14,277 | $4,214 | 29.5% |
| 95912 | Nerve conduction, 11-12 studies | Facility | 2023 | 24 | 24 | $15,120 | $3,305 | 21.9% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Facility | 2023 | 16 | 29 | $20,010 | $3,155 | 15.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 26 | 26 | $13,670 | $3,020 | 22.1% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2023 | 58 | 71 | $13,444 | $2,846 | 21.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 23 | $13,340 | $2,803 | 21.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 17 | $6,970 | $1,706 | 24.5% |
| 76942 | Ultrasonic guidance for needle placement | Facility | 2023 | 20 | 42 | $4,620 | $1,153 | 25.0% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2023 | 45 | 64 | $4,480 | $996.07 | 22.2% |
| 95873 | Electrical stimulation for guidance with injection of chemical for paralysis of nerve muscle | Facility | 2023 | 20 | 41 | $3,280 | $708.89 | 21.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 98 | 146 | $64,240 | $17,895 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 79 | 98 | $30,510 | $8,310 | 27.2% |
| 95913 | Nerve conduction, 13 or more studies | Facility | 2022 | 45 | 45 | $33,300 | $7,429 | 22.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 36 | 36 | $24,120 | $5,833 | 24.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 40 | 40 | $20,800 | $4,912 | 23.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 34 | 42 | $18,060 | $3,715 | 20.6% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Facility | 2022 | 14 | 30 | $20,700 | $3,478 | 16.8% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2022 | 57 | 75 | $14,496 | $3,068 | 21.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 22 | 30 | $6,450 | $2,719 | 42.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 23 | $9,430 | $2,554 | 27.1% |
About Dr. David Simpson, M.D
Dr. David Simpson, M.D is a Neurology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316918592.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Simpson, M.D has received a total of $638,492 in payments from pharmaceutical and medical device companies, with $27,970 received in 2024. These payments were reported across 883 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($227,252).
As a Medicare-enrolled provider, Simpson has provided services to 2,433 Medicare beneficiaries, totaling 3,189 services with total Medicare billing of $283,282. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location New York, NY
- Active Since 01/27/2006
- Last Updated 05/22/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1316918592
Products in Payments
- Qutenza (Drug) $155,842
- BOTOX (Biological) $124,313
- XEOMIN (Biological) $91,653
- Xeomin (Biological) $58,492
- Multiple Products (Biological) $37,667
- DYSPORT (Drug) $18,179
- BOTOX (Drug) $13,102
- Dysport 300 U-1 (Drug) $9,358
- VYVGART HYTRULO (Drug) $9,104
- Hizentra (Biological) $6,252
- ONPATTRO (Drug) $5,661
- BOTOX NEURO REHAB (Drug) $5,035
- Soliris (Drug) $3,060
- ULTOMIRIS (Biological) $2,753
- GIVLAARI (Drug) $2,250
- Dysport (Drug) $2,216
- BOTOX - NEUROLOGY (Drug) $1,641
- SOLIRIS (Biological) $790.08
- QUTENZA (Drug) $678.95
- INTELLIS ADAPTIVESTIM (Device) $592.21
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in New York
Dr. Stephen Krieger, Md, MD
Neurology — Payments: $1.6M
Neurology $1.6M
Dr. David Dodick, M.d, M.D
Neurology — Payments: $765,174
Neurology $765,174
Steven Wolf, Md, MD
Neurology — Payments: $585,108
Neurology $585,108
Dr. Alexander Shtilbans, Md, Ph.d, MD, PH.D
Neurology — Payments: $550,165
Neurology $550,165
Dr. Fred Lublin, M.d, M.D
Neurology — Payments: $549,390
Neurology $549,390
Dr. Alcibiades Rodriguez, Md, MD
Neurology — Payments: $540,659
Neurology $540,659